Zomedica (ZOMDF) Stock Price, News & Analysis

Company Overview

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.

Key Stats

• Today's Range: $0.08 to $0.09
• 50-Day Range: $0.07 to $0.11
• 52-Week Range: $0.04 to $0.16
• Volume: 509,386 shs
• Average Volume: 524,933 shs
• Market Capitalization: $85.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Zomedica Stock Analysis - MarketRank™

Zomedica scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Zomedica.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Zomedica is -4.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zomedica is -4.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Zomedica has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of Zomedica has been sold short.

Short Interest Ratio / Days to Cover

Zomedica has a short interest ratio ("days to cover") of 0.11, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Zomedica has recently decreased by 11.88%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Zomedica does not currently pay a dividend.

Dividend Growth

Zomedica does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Zomedica to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Zomedica insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.75% of the stock of Zomedica is held by insiders.

Percentage Held by Institutions

8.95% of the stock of Zomedica is held by institutions.

Company Calendar

• Today: 7/26/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:ZOMDF
• Previous Symbol: OTC:ZOMDF
• CIK: 1684144
• Web: www.zomedica.com
• Phone: 734 369 2555
• Fax: N/A
• Employees: 50
• Year Founded: 2015

Profitability

• EPS (Trailing Twelve Months): ($0.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$81.86 million
• Net Margins: -65.92%
• Pretax Margin: -66.31%
• Return on Equity: -19.20%
• Return on Assets: -17.54%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.01
• Quick Ratio: 6.33

Sales & Book Value

• Annual Sales: $32.03 million
• Price / Sales: 2.67
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.12 per share
• Price / Book: 0.73

Miscellaneous

• Outstanding Shares: 979,950,000
• Free Float: 913,803,000
• Market Cap: $85.45 million
• Optionable: N/A
• Beta: 1.34